Motavizumab's Data Integrity Worries Grow As FDA Shows Interest In Lawsuit

Alongside FDA's concerns about possible bias in the Phase III clinical trials of Rezield (motavizumab), MedImmune faces an accusation of data suppression from a former employee who alleges he was fired for bringing up problems with sample screening